vs
Side-by-side financial comparison of Navitas Semiconductor Corp (NVTS) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.3M, roughly 1.3× Navitas Semiconductor Corp). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -436.1%, a 375.7% gap on every dollar of revenue. On growth, Protalix BioTherapeutics, Inc. posted the faster year-over-year revenue change (-49.9% vs -59.4%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-8.2M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -43.9%).
Navitas Semiconductor Corp is a leading global semiconductor firm specializing in gallium nitride (GaN) power integrated circuits. Its high-efficiency, compact power solutions serve consumer electronics, electric vehicles, renewable energy, and industrial sectors, with clients spanning North America, Asia, and Europe.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
NVTS vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.3M | $9.1M |
| Net Profit | $-31.8M | $-5.5M |
| Gross Margin | 38.1% | 49.4% |
| Operating Margin | -567.3% | -51.1% |
| Net Margin | -436.1% | -60.3% |
| Revenue YoY | -59.4% | -49.9% |
| Net Profit YoY | 20.2% | -184.8% |
| EPS (diluted) | $-0.14 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.3M | $9.1M | ||
| Q3 25 | $10.1M | $17.9M | ||
| Q2 25 | $14.5M | $15.7M | ||
| Q1 25 | $14.0M | $10.1M | ||
| Q4 24 | $18.0M | $18.2M | ||
| Q3 24 | $21.7M | $18.0M | ||
| Q2 24 | $20.5M | $13.5M | ||
| Q1 24 | $23.2M | — |
| Q4 25 | $-31.8M | $-5.5M | ||
| Q3 25 | $-19.2M | $2.4M | ||
| Q2 25 | $-49.1M | $164.0K | ||
| Q1 25 | $-16.8M | $-3.6M | ||
| Q4 24 | $-39.9M | $6.5M | ||
| Q3 24 | $-18.7M | $3.2M | ||
| Q2 24 | $-22.3M | $-2.2M | ||
| Q1 24 | $-3.7M | — |
| Q4 25 | 38.1% | 49.4% | ||
| Q3 25 | 37.9% | 53.4% | ||
| Q2 25 | 16.1% | 62.5% | ||
| Q1 25 | 37.9% | 19.1% | ||
| Q4 24 | 12.4% | 78.7% | ||
| Q3 24 | 39.7% | 53.4% | ||
| Q2 24 | 39.0% | 29.8% | ||
| Q1 24 | 41.1% | — |
| Q4 25 | -567.3% | -51.1% | ||
| Q3 25 | -192.0% | 11.9% | ||
| Q2 25 | -149.4% | 7.5% | ||
| Q1 25 | -180.5% | -41.0% | ||
| Q4 24 | -216.9% | 39.6% | ||
| Q3 24 | -133.6% | 22.2% | ||
| Q2 24 | -152.1% | -18.0% | ||
| Q1 24 | -136.2% | — |
| Q4 25 | -436.1% | -60.3% | ||
| Q3 25 | -190.2% | 13.2% | ||
| Q2 25 | -338.7% | 1.0% | ||
| Q1 25 | -120.1% | -35.8% | ||
| Q4 24 | -221.7% | 35.6% | ||
| Q3 24 | -86.4% | 18.0% | ||
| Q2 24 | -109.1% | -16.4% | ||
| Q1 24 | -15.9% | — |
| Q4 25 | $-0.14 | $-0.06 | ||
| Q3 25 | $-0.09 | $0.03 | ||
| Q2 25 | $-0.25 | $0.00 | ||
| Q1 25 | $-0.09 | $-0.05 | ||
| Q4 24 | $-0.22 | $0.10 | ||
| Q3 24 | $-0.10 | $0.03 | ||
| Q2 24 | $-0.12 | $-0.03 | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $236.9M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $443.7M | $48.2M |
| Total Assets | $500.5M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $236.9M | $14.7M | ||
| Q3 25 | $150.6M | $13.6M | ||
| Q2 25 | $161.2M | $17.9M | ||
| Q1 25 | $75.1M | $19.5M | ||
| Q4 24 | $86.7M | $19.8M | ||
| Q3 24 | $98.3M | $27.4M | ||
| Q2 24 | $111.7M | $23.4M | ||
| Q1 24 | $128.9M | — |
| Q4 25 | $443.7M | $48.2M | ||
| Q3 25 | $371.0M | $52.9M | ||
| Q2 25 | $388.9M | $49.9M | ||
| Q1 25 | $341.8M | $45.2M | ||
| Q4 24 | $348.0M | $43.2M | ||
| Q3 24 | $380.8M | $32.4M | ||
| Q2 24 | $388.1M | $28.6M | ||
| Q1 24 | $397.9M | — |
| Q4 25 | $500.5M | $82.3M | ||
| Q3 25 | $430.2M | $82.3M | ||
| Q2 25 | $449.4M | $78.5M | ||
| Q1 25 | $370.8M | $73.9M | ||
| Q4 24 | $390.0M | $73.4M | ||
| Q3 24 | $419.4M | $61.6M | ||
| Q2 24 | $439.1M | $91.5M | ||
| Q1 24 | $467.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.1M | $2.0M |
| Free Cash FlowOCF − Capex | $-8.2M | $1.6M |
| FCF MarginFCF / Revenue | -111.8% | 17.8% |
| Capex IntensityCapex / Revenue | 0.7% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-44.4M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.1M | $2.0M | ||
| Q3 25 | $-10.0M | $-3.7M | ||
| Q2 25 | $-11.2M | $-5.2M | ||
| Q1 25 | $-13.5M | $-5.1M | ||
| Q4 24 | $-10.2M | $4.0M | ||
| Q3 24 | $-13.7M | $4.1M | ||
| Q2 24 | $-15.1M | $-3.6M | ||
| Q1 24 | $-19.8M | — |
| Q4 25 | $-8.2M | $1.6M | ||
| Q3 25 | $-10.7M | $-4.2M | ||
| Q2 25 | $-11.9M | $-5.7M | ||
| Q1 25 | $-13.6M | $-5.4M | ||
| Q4 24 | $-10.8M | $3.6M | ||
| Q3 24 | $-14.3M | $4.0M | ||
| Q2 24 | $-17.9M | $-3.8M | ||
| Q1 24 | $-22.7M | — |
| Q4 25 | -111.8% | 17.8% | ||
| Q3 25 | -106.1% | -23.7% | ||
| Q2 25 | -82.2% | -36.2% | ||
| Q1 25 | -96.8% | -53.0% | ||
| Q4 24 | -59.8% | 19.6% | ||
| Q3 24 | -65.9% | 22.4% | ||
| Q2 24 | -87.3% | -28.1% | ||
| Q1 24 | -97.9% | — |
| Q4 25 | 0.7% | 4.4% | ||
| Q3 25 | 7.0% | 2.8% | ||
| Q2 25 | 4.7% | 2.8% | ||
| Q1 25 | 0.3% | 3.0% | ||
| Q4 24 | 3.1% | 2.3% | ||
| Q3 24 | 2.6% | 0.5% | ||
| Q2 24 | 13.4% | 1.3% | ||
| Q1 24 | 12.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NVTS
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
